Dysautonomia in anti-Hu paraneoplastic neurological syndromes

被引:1
|
作者
Villagran-Garcia, Macarena [1 ,2 ]
Farina, Antonio [1 ,2 ,3 ]
Arzalluz-Luque, Joaquin [1 ,4 ]
Campetella, Lucia [1 ]
Muniz-Castrillo, Sergio [1 ,5 ]
Benaiteau, Marie [1 ]
Peter, Elise [1 ,2 ]
Dumez, Pauline [1 ,2 ]
Wucher, Valentin [1 ,2 ]
Dhairi, Maroua [1 ]
Picard, Geraldine [1 ]
Rafiq, Marie [6 ]
Psimaras, Dimitri [7 ,8 ]
Rogemond, Veronique [1 ,2 ]
Joubert, Bastien [1 ,2 ]
Honnorat, Jerome [1 ,2 ]
机构
[1] Hosp Civils Lyon, Hop Neurol, French Reference Ctr Paraneoplast Neurol Syndromes, 59 Bd Pinel, F-69677 Bron, France
[2] Univ Claude Bernard Lyon 1, CNRS UMR 5284, UCBL,U1314, INSERM,MeLiS, F-69008 Lyon, France
[3] Univ Florence, Dept Neurosci Psychol Pharmacol & Child Hlth, I-50139 Florence, Italy
[4] Hosp Univ Virgen Macarena, Dept Neurol, Seville 41009, Spain
[5] Stanford Univ, Ctr Sleep Sci & Med, Palo Alto, CA 94304 USA
[6] Univ Hosp Toulouse, Dept Neurol, F-31300 Toulouse, France
[7] Hosp Grp Pitie Salpetriere, AP HP, Neurol Dept Mazarin 2, F-75013 Paris, France
[8] Paris Brain Inst, Inst Cerveau & Moelle Epiniere ICM, Inserm, CNRS, F-75013 Paris, France
关键词
Dysautonomia; Autonomic function; Paraneoplastic autoimmunity; Hu; ANNA-1; POSITIVE PATIENTS; ENCEPHALOMYELITIS; TUMOR;
D O I
10.1007/s00415-024-12278-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and objectives Dysautonomia has been associated with paraneoplastic neurological syndrome (PNS)-related mortality in anti-Hu PNS, but its frequency and spectrum remain ill-defined. We describe anti-Hu patients with dysautonomia, estimate its frequency, and compare them to patients without dysautonomia. Methods Patients with anti-Hu antibodies diagnosed in the study centre (1990-2022) were retrospectively reviewed; those with autonomic signs and symptoms were identified. Results Among 477 anti-Hu patients, 126 (26%) had dysautonomia (the only PNS manifestation in 7/126, 6%); gastrointestinal (82/126, 65%), cardiovascular (64/126, 51%), urogenital (24/126, 19%), pupillomotor/secretomotor (each, 11/126, 9%), and central hypoventilation (10/126, 8%). Patients with isolated CNS involvement less frequently had gastrointestinal dysautonomia than those with peripheral (alone or combined with CNS) involvement (7/23, 30% vs. 31/44, 70% vs. 37/52, 71%; P = 0.002); while more frequently central hypoventilation (7/23, 30% vs. 1/44, 2.3% vs. 2/52, 4%; P < 0.001) and/or cardiovascular alterations (18/23, 78% vs. 20/44, 45% vs. 26/52, 50%; P = 0.055). Median [95% CI] overall survival was not significantly different between patients with (37 [17; 91] months) or without dysautonomia (28 [22; 39] months; P = 0.78). Cardiovascular dysautonomia (HR: 1.57, 95% CI [1.05; 2.36]; P = 0.030) and central hypoventilation (HR: 3.51, 95% CI [1.54; 8.01]; P = 0.003) were associated with a higher risk of death, and secretomotor dysautonomia a lower risk (HR: 0.28, 95% CI [0.09; 0.89]; P = 0.032). Patients with cardiovascular dysautonomia dying <= 1 year from clinical onset had severe CNS (21/27, 78%), frequently brainstem (13/27, 48%), involvement. Discussion Anti-Hu PNS dysautonomia is rarely isolated, frequently gastrointestinal, cardiovascular and urogenital. CNS dysfunction, particularly brainstem, associates with lethal cardiovascular alterations and central hypoventilation, while peripheral involvement preferentially associates with gastrointestinal or secretomotor dysautonomia, being the latest more indolent.
引用
收藏
页码:3359 / 3369
页数:11
相关论文
共 50 条
  • [1] Paraneoplastic syndromes associated with anti-Hu antibodies
    Senties-Madrid, H
    Vega-Boada, F
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2001, 3 (02): : 94 - +
  • [2] Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies
    Benyahia, B
    Liblau, R
    Merle-Béral, H
    Tourani, JM
    Dalmau, J
    Delattre, JY
    ANNALS OF NEUROLOGY, 1999, 45 (02) : 162 - 167
  • [3] Paraneoplastic Parkinsonism-Dysautonomia Due To Anti-Hu Antibodies
    Ricigliano, Vito
    Fossati, Barbara
    NEUROLOGY, 2020, 94 (15)
  • [4] Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes
    Bastiaansen, Anna E. M.
    de Jongste, Adriaan H. C.
    de Bruijn, Marienke A. A. M.
    Crijnen, Yvette S.
    Schreurs, Marco W. J.
    Verbeek, Marcel M.
    Dumoulin, Daphne W.
    Taal, Walter
    Titulaer, Maarten J.
    Smitt, Peter A. E. Sillevis
    NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)
  • [5] Disturbance in the serum IgC subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes
    Klotz, M
    Funke, D
    Strittmatter, M
    Schimrigk, K
    Huwer, H
    Blaes, F
    AUTOANTIGENS AND AUTOANTIBODIES: DIAGNOSTIC TOOLS AND CLUES TO UNDERSTANDING AUTOIMMUNITY, 2000, 1 : 618 - 618
  • [6] Genetic alterations in tumors and immune tolerance breackdown in anti-hu associated paraneoplastic neurological syndromes
    Pegat, Antoine
    Vogrig, Alberto
    Honnorat, Jerome
    Attignon, Valery
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 : S9 - S9
  • [7] Disturbance in the serum IgG subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes
    Blaes, F
    Klotz, M
    Funke, D
    Strittmatter, M
    Kraus, J
    Kaps, M
    EUROPEAN JOURNAL OF NEUROLOGY, 2002, 9 (04) : 369 - 372
  • [8] Various clinical features of patients with anti-Hu associated paraneoplastic neurological syndromes: An observational study
    Li, Jia
    Lin, Weihong
    MEDICINE, 2018, 97 (18)
  • [9] Trismus as the Initial Presentation of Anti-Hu Paraneoplastic Neurological Syndrome
    Mitarnun, Witoon
    Apiwattanakul, Metha
    Chindavech, Narin
    Sombat, Benyapha
    Jantapatsakun, Suttanon
    Sornnuwat, Pheeracha
    NEUROHOSPITALIST, 2024, 14 (03): : 336 - 338
  • [10] Long-term evolution of anti-Hu antibody (Hu-ab) titres in patients with paraneoplastic neurological syndromes
    Lladó, A
    Mannucci, P
    Carpentier, A
    Saiz, A
    Delattre, JY
    Graus, F
    JOURNAL OF NEUROLOGY, 2004, 251 : 168 - 168